Boston Scientific Lowers Full-Year 2026 Financial Outlook

Boston Scientific Corp. lowered its full-year 2026 financial guidance after reporting second-quarter results on July 29, 2026. The medical devices company now expects adjusted earnings between $3.28 and $3.32 per share, a decrease from its previous projection of $3.34 to $3.41.

In addition to the earnings cut, the company reduced its net sales growth forecast to 5.5-6.5%, down from the earlier estimate of 7.0-8.5%. Organic net sales growth was similarly lowered to 5-6% from 6.5-8.0%. For the third quarter, the company projects adjusted earnings of $0.80 to $0.82 per share with organic net sales growth between 3 and 5 percent.

Despite the reduced outlook, the company's stock rose 4.08 percent, increasing by $1.88 to trade at $48.00 on the New York Stock Exchange during Wednesday's pre-market session.